Compare PubMatic Inc (PUBM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Zimmer Biomet Holdings Inc — how do they compare? PubMatic Inc trades at $18.64 (market cap $850.88M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 19.9× PubMatic Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PUBM | ZBH | |
|---|---|---|
Market Cap | $850.88M | $16.95B |
Volume | 997,698 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $19.18 | $103.98 |
52-Week Low | $6.28 | $79.58 |
Typical Hold Time | 40 Days | 89 Days |
Enterprise Value | $754.01M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $18.68, up 0.59% today, with a bullish technical signal supported by moving averages. The company reported a net loss of $14.46 million in 2025 despite revenue of $282.93 million, though recent quarters have shown earnings beats. Analyst sentiment is positive with a $19.89 consensus price target and 11 buy ratings. Recent news highlights AI-driven ad tech growth and leadership changes, including a new global chief revenue officer.
The outlook is cautiously optimistic given strong analyst support and technical momentum, but profitability challenges and competitive pressures in digital advertising pose risks. Revenue growth and margin improvement in higher-margin segments like mobile and CTV are key catalysts for upside, while execution risks and market volatility remain concerns.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
